This spontaneous case was reported by a patient and describes the occurrence of DYSPEPSIA (Indigestion), CHEST PAIN (Chest pain), INTERVERTEBRAL DISC DEGENERATION (Degenerative disc disease), ARTHRITIS (Arthritis) and DRUG INEFFECTIVE (Oxycontin Stopped Working) in a 42-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination. Co-suspect products included non-company products ADALIMUMAB (HUMIRA) solution for injection for Hidradenitis suppurativa and OXYCODONE HYDROCHLORIDE (OXYCONTIN) solution for injection for Arthritis and Degenerative disc disease. No Medical History information was reported. On 26-Jan-2022, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 22-Feb-2022, received second dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) in pre filled pen and OXYCODONE HYDROCHLORIDE (OXYCONTIN) (unknown route) at an unspecified dose. In 2022, the patient experienced DYSPEPSIA (Indigestion) and CHEST PAIN (Chest pain). On an unknown date, the patient experienced INTERVERTEBRAL DISC DEGENERATION (Degenerative disc disease), ARTHRITIS (Arthritis) and DRUG INEFFECTIVE (Oxycontin Stopped Working). In 2022, DYSPEPSIA (Indigestion) and CHEST PAIN (Chest pain) had resolved. At the time of the report, INTERVERTEBRAL DISC DEGENERATION (Degenerative disc disease), ARTHRITIS (Arthritis) and DRUG INEFFECTIVE (Oxycontin Stopped Working) had not resolved. Concomitant medication list was not provided. Treatment information was not provided. Reporters causality for HUMIRA (Solution for injection in pre-filled pen)(ADALIMUMAB) for events, Degenerative disc disease, Lack of drug effect, Indigestion, Arthritis and Chest pain were not reported. Reporters causality for OXYCONTIN(OXYCODONE HYDROCHLORIDE) for events, Degenerative disc disease, Lack of drug effect, Indigestion, Arthritis and Chest pain were not reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Company Comment: This is a spontaneous case concerning a 42-year-old female patient with no reported medical history, who experienced the non-serious, unexpected event of Drug Ineffective (reported as "Oxycontin not Working") on an unknown date after receiving a dose of mRNA-1273 COVID-19 vaccine and the co-suspect, non-company products Adalimumab and Oxycodone Hydrochloride along with other non-serious events. No further information on risk factors, co morbidities, clinical course and management of the event was available in the report. It was reported that the outcome of the event has not. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Sender's Comments: This is a spontaneous case concerning a 42-year-old female patient with no reported medical history, who experienced the non-serious, unexpected event of Drug Ineffective (reported as "Oxycontin not Working") on an unknown date after receiving a dose of mRNA-1273 COVID-19 vaccine and the co-suspect, non-company products Adalimumab and Oxycodone Hydrochloride along with other non-serious events. No further information on risk factors, co morbidities, clinical course and management of the event was available in the report. It was reported that the outcome of the event has not. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.